Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Assets (2018 - 2025)

China SXT Pharmaceuticals (SXTC) has 8 years of Assets data on record, last reported at $21.7 million in Q1 2025.

  • For Q1 2025, Assets fell 6.33% year-over-year to $21.7 million; the TTM value through Mar 2025 reached $21.7 million, down 6.33%, while the annual FY2025 figure was $21.7 million, 6.33% down from the prior year.
  • Assets reached $21.7 million in Q1 2025 per SXTC's latest filing, down from $23.1 million in the prior quarter.
  • Across five years, Assets topped out at $34.5 million in Q1 2021 and bottomed at $21.7 million in Q1 2025.
  • Average Assets over 5 years is $28.5 million, with a median of $29.6 million recorded in 2023.
  • Peak YoY movement for Assets: soared 59.19% in 2021, then decreased 21.75% in 2024.
  • A 5-year view of Assets shows it stood at $34.5 million in 2021, then dropped by 2.9% to $33.5 million in 2022, then decreased by 11.9% to $29.6 million in 2023, then fell by 21.75% to $23.1 million in 2024, then dropped by 6.33% to $21.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Assets were $21.7 million in Q1 2025, $23.1 million in Q1 2024, and $29.6 million in Q1 2023.